Soleus Capital Management, L.P. Protagonist Therapeutics, Inc Transaction History

Soleus Capital Management, L.P.

  • $1.18 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
SELL
$21.79 - $32.15 $1.06 Million - $1.56 Million
-48,500 Reduced 58.43%
34,500 $998,000
Q4 2023

Feb 14, 2024
BUY
$14.05 - $23.44 $1.17 Million - $1.95 Million
83,000 New
83,000 $1.9 Million
Q2 2023

Aug 14, 2023
BUY
$18.02 - $29.36 $717,196 - $1.17 Million
39,800 New
39,800 $1.1 Million
Q4 2022

Feb 14, 2023
BUY
$7.36 - $11.17 $1.74 Million - $2.64 Million
236,000 New
236,000 $2.57 Million

Others Institutions Holding PTGX

# of Institutions
247
Shares Held
56.4M
Call Options Held
76.3K
Put Options Held
114K
View Full List

About Protagonist Therapeutics, Inc

PTGX Quotes by TradingView
  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Soleus Capital Management, L.P. Portfolio

Follow Soleus Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Soleus Capital Management, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email